Table 3.
Summary of previously published SOD1 transgenic models
| Transgenic line | h/m SOD1 ratio | Onset of disease | Reference |
|---|---|---|---|
| h-SOD1 | 1–10 | No disease | (Epstein et al., 1987) |
| (Ceballos-Picot et al., 1991) | |||
| (Gurney et al., 1994) | |||
| (Wong et al., 1995) | |||
| (Bruijn et al., 1997) | |||
| m-SOD1 null | No SOD1 | No disease | (Reaume et al., 1996) |
| h-G37R | 10–12 | 3.5–4 months | (Wong et al., 1995) |
| 4–5 | 6–8 months | (Wong et al., 1995) | |
| h-G85R | 1 | 8–10 months | (Bruijn et al., 1997) |
| 0.2 | 12–14 months | (Bruijn et al., 1997) | |
| m-G86R | 1 | 3–4 months | (Ripps et al., 1995) |
| m-G86R | Restricted to astocytes | No disease | (Gong et al., 2000) |
| h-G93A | 4 | 4–6 months | (Gurney et al., 1994) |
h, Human SOD1; m, mouse SOD1 transgene.